Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Tonix Pharma ( (TNXP) ) has provided an announcement.
Tonix Pharmaceuticals announced the FDA’s acceptance of its New Drug Application for TNX-102 SL, a non-opioid analgesic for fibromyalgia. This acceptance marks potential progress toward introducing the first new fibromyalgia drug in over 15 years, potentially reducing reliance on opioids, and signifies a significant milestone as Tonix prepares for potential market approval in 2025.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp is a fully integrated biopharmaceutical company focusing on therapies for pain management and vaccines addressing public health challenges, with a development portfolio centered on central nervous system disorders. Its priority is advancing TNX-102 SL, a product candidate for managing fibromyalgia.
YTD Price Performance: -95.89%
Average Trading Volume: 55,709,789
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $99.05M
For an in-depth examination of TNXP stock, go to TipRanks’ Stock Analysis page.
